Should you buy Co-Diagnostics stock now?
No, the technical signal for Co-Diagnostics is currently SELL. Co-Diagnostics trades at $1.42 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.470 with falling momentum (signal: -0.456); RSI is at 30.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $45.00 points to 3,069.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Co-Diagnostics stock?
The average analyst price target for Co-Diagnostics is $45.00. The current price is $1.42, which gives an upside of 3,069.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $40.50 and $49.50.
Is Co-Diagnostics a dividend stock?
No, Co-Diagnostics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Co-Diagnostics stock?
Co-Diagnostics is rated as a stock with extreme risk. the annual standard deviation is 354.0%, which classifies the stock as extreme risk.
Is Co-Diagnostics overvalued?
No, Co-Diagnostics is considered undervalued based on the analyst price target (3,069.0% upside). Co-Diagnostics has the following valuation ratios: a P/S ratio of 7.7, a P/B ratio of 0.3. The analyst price target suggests that the stock is undervalued by 3,069.0%.
Is Co-Diagnostics overbought?
No, Co-Diagnostics is not overbought. RSI is at 30.3 (neutral zone). The technical indicators show: RSI is at 30.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 31.9% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish).
When is the next Co-Diagnostics earnings report?
Co-Diagnostics reports its next earnings on August 13, 2026. The stock currently trades at $1.42. The RSI is at 30.3, so the report can reinforce the current technical trend.
Is Co-Diagnostics shorted?
Yes, Co-Diagnostics is shorted with 9.6% of the free float sold short. This is a high level of short selling, which suggests some investors are betting on falling prices. Positive surprises can lead to a moderate short squeeze. Data is updated daily based on official filings with the SEC.
Are insiders buying Co-Diagnostics stock?
No, insiders are not buying Co-Diagnostics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 51,836 $ worth of shares were sold. Across the last 20 reported transactions, the split is 2 purchases and 18 sales, with a net 1,420,036 $ sold. Active sellers include Egan Dwight H, Brown Brian Lee, Abbott Richard David. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Co-Diagnostics a good stock?
Based on our total score, Co-Diagnostics is rated as a poor stock with a total score of 22 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 36/100, Quality: 7/100. In addition: analysts see 3,069.0% upside to the price target; technical signal: Strong Sell. Whether Co-Diagnostics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Co-Diagnostics stock?
The outlook for Co-Diagnostics based on current data: the average analyst price target is $45.00 (+3,069.0%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/13/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Co-Diagnostics stock falling?
Co-Diagnostics is falling right now. The technical indicators show: the price is 31.9% below the 20-day average; MACD is negative with falling momentum (bearish signal); short interest is 9.6% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Co-Diagnostics go?
The average analyst price target for Co-Diagnostics is $45.00, which corresponds to a potential gain of 3,069.0% from the current price of $1.42. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Co-Diagnostics fall?
We lack enough history to give a specific floor for Co-Diagnostics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Co-Diagnostics do?
Co-Diagnostics, Inc. laver molekylær diagnostik og sælger reagenser til test, der analyserer DNA og RNA. De tjener penge på at udvikle og sælge PCR-diagnostiske tests globalt. Virksomheden er kendt for at lave tests for sygdomme som COVID-19, tuberkulose og hepatitis. Co-Diagn... The company belongs to the Sundhed sector, more specifically the Medicinprodukter industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Co-Diagnostics as an investment.
Did Co-Diagnostics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Co-Diagnostics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Co-Diagnostics making money or losing money?
We have no current profitability data for Co-Diagnostics. See the latest report in the earnings history above.
Can Co-Diagnostics go bankrupt?
The bankruptcy risk of Co-Diagnostics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -24.48 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 18% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Co-Diagnostics have a lot of debt?
No, Co-Diagnostics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 18%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
